Jade Biosciences, Inc.

Based on the Company s current operating plan, Jade believes that its cash and cash equivalents as of June 30, 2025 will enable it to fund its operating expenses and capital expenditure requirements through the end of 2027.

SEC original ↗Jade Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

The Company expects that its existing cash and cash equivalents, and investments of $ 461.2 million as of June 30, 2026 , are sufficient to fund its planned operating expenses and capital expenditure requirements for at least twelve months from the date these unaudited condensed consolidated financial statements were issued.

SEC original ↗Jade Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

government-sponsored agency securities 61,045 ( 246 ) 60,799 Commercial paper 3,939 3,939 Corporate debt securities 178,051 5 ( 200 ) 177,856 Total $ 354,516 $ 7 $ ( 568 ) $ 353,955 8 JADE BIOSCIENCES, INC.

SEC original ↗Jade Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

government-sponsored agency securities 61,310 25 ( 20 ) 61,315 Commercial paper 8,904 3 8,907 Corporate debt securities 122,468 104 ( 1 ) 122,571 Total $ 247,563 $ 178 $ ( 21 ) $ 247,720 As of both June 30, 2026 and December 31, 2025, all of the Company s investments were available to the Company for use in current operations.

SEC original ↗Jade Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

government-sponsored agency securities 10,045 51,270 61,315 Commercial paper 8,907 8,907 Corporate debt securities 60,659 61,912 122,571 Total $ 129,504 $ 118,216 $ 247,720 9 JADE BIOSCIENCES, INC.

SEC original ↗Jade Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

government-sponsored agency securities 8,294 52,505 60,799 Commercial paper 3,939 3,939 Corporate debt securities 164,191 13,665 177,856 Total $ 277,247 $ 181,470 $ $ 458,717 December 31, 2025 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 87,989 $ $ $ 87,989 Current investments: U.

SEC original ↗Jade Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

( Jade ) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the quarter ending June 30, 2025, and provided a corporate update.

SEC original ↗Jade Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases.

SEC original ↗Jade Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

The words opportunity, potential, milestones, pipeline, can, goal, strategy, target, anticipate, achieve, believe, contemplate, continue, could, estimate, expect, intends, may, plan, possible, project, should, will, would and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

SEC original ↗Jade Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

Jade is focused on developing therapies to address critical unmet needs in autoimmune diseases.

SEC original ↗Jade Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

The Company is led by Pre-Merger Jade s management team and focuses on developing differentiated biologic therapies for patients living with autoimmune diseases.

SEC original ↗Jade Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

SEC original ↗Jade Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

Should one or more of these risks or uncertainties materialize, or should any of Jade s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

SEC original ↗Jade Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

Legal Proceedings 38 Item 1A.

SEC original ↗Jade Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Given the Company s uncertainty regarding future taxable income, the Company maintains a full valuation allowance on its domestic deferred tax assets.

SEC original ↗Jade Biosciences, Inc. — 10-Q Quarterly report10-QAug 10, 2026